Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Debrisoquin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | THRB | P10828 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.83 |
| ▸ | TMPRSS2 | O15393 | 5/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | MAOA | P21397 | 1/20 | 0.79 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Debrisoquin SCHEMBL29711278 | 0.91 | LMNA (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL11656689 | 0.91 | LMNA (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL122316 | 0.91 | LMNA (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL29390380 | 0.89 | TMPRSS2 (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL309184 | 0.89 | TMPRSS2 (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL17186394 | 0.76 | TMPRSS2 (0.74) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL29560844 | 0.75 | NOTUM (0.68) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL546055 | 0.75 | NOTUM (0.68) | LMNAHSD17B10THRBTSHRPMP22 | |
| Hydrochloric Acid SCHEMBL17186387 | 0.74 | TMPRSS2 (0.71) | LMNAHSD17B10THRBTSHRPMP22 | |
| Hydrochloric Acid SCHEMBL1075430 | 0.74 | NOTUM (0.66) | LMNAHSD17B10THRBTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371387-B2 | Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-06-21 | — | — | US | claimed |
| US-20140234343-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF ISCHEMIC CARDIAC DISEASE, COMPRISING INHIBITOR AGAINST AGE-ALBUMIN SYNTHESIS OR RELEASE OF MONONUCLEAR PHAGOCYTE SYSTEM CELLS AS ACTIVE INGREDIENT | NSAGE CORP. (KR) | 2014-08-21 | — | — | US | claimed |
| US-20130131006-A1 | METHOD FOR INHIBITING THE INDUCTION OF CELL DEATH BY INHIBITING THE SYNTHESIS OR SECRETION OF AGE-ALBUMIN IN CELLS OF THE MONONUCLEAR PHAGOCYTE SYSTEM | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2013-05-23 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5036106-A | Antiarrhythmia agents, bretylium tosylate | BACANER MARVIN B (US) | 1991-07-30 | — | — | US | disclosed |
| US-5036106-A | Antiarrhythmia agents, bretylium tosylate | BACANER MARVIN B (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | SLC6A2 632/4885LMNA 1462/4885HSD17B10 4077/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SLC6A2 286/4885LMNA 2584/4885HSD17B10 1790/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | SLC6A2 210/4885LMNA 2103/4885HSD17B10 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.